Company Overview of Xenothera SAS
Xenothera SAS, a biotechnology company, develops a platform with embedded technology that renovates immunological treatments. It develops new therapeutic modes in various domains from immunomodulation to infectious diseases. The company’s therapeutic modes are based on animal genetics and mastery of immunology processes. It renovates passive immunotherapy by marketing a new generation of hyperimmune polyclonal sera. Xenothera SAS was founded in 2014 and is based in Nantes, France.
1 rue Gaston Weil
Founded in 2014
33 7 70 21 377
33 7 43 50 228
Key Executives for Xenothera SAS
Similar Private Companies By Industry
|Acticor Biotech SAS||Europe|
|Aelis Farma S.A.S.||Europe|
|Aenitis Technologies SAS||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Xenothera SAS, please visit www.xenothera.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.